世界のE3ユビキチンタンパク質リガーゼXIAP市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV05501)
◆英語タイトル:Global E3 Ubiquitin Protein Ligase XIAP Market Insights and Forecast to 2026
◆商品コード:QYR20NV05501
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:111
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートはE3ユビキチンタンパク質リガーゼXIAPの世界市場について調査・分析した資料です。種類別(ASTX-660、FL-118、AD-O53.2、LCL-161、SM-1200、その他)の市場規模、用途別(固形腫瘍、卵管がん、肺がん、腹膜がん、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別E3ユビキチンタンパク質リガーゼXIAPの競争状況、市場シェア
・世界のE3ユビキチンタンパク質リガーゼXIAP市場:種類別市場規模 2015年-2020年(ASTX-660、FL-118、AD-O53.2、LCL-161、SM-1200、その他)
・世界のE3ユビキチンタンパク質リガーゼXIAP市場:種類別市場規模予測 2021年-2026年(ASTX-660、FL-118、AD-O53.2、LCL-161、SM-1200、その他)
・世界のE3ユビキチンタンパク質リガーゼXIAP市場:用途別市場規模 2015年-2020年(固形腫瘍、卵管がん、肺がん、腹膜がん、その他)
・世界のE3ユビキチンタンパク質リガーゼXIAP市場:用途別市場規模予測 2021年-2026年(固形腫瘍、卵管がん、肺がん、腹膜がん、その他)
・北米のE3ユビキチンタンパク質リガーゼXIAP市場分析:米国、カナダ
・ヨーロッパのE3ユビキチンタンパク質リガーゼXIAP市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのE3ユビキチンタンパク質リガーゼXIAP市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のE3ユビキチンタンパク質リガーゼXIAP市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのE3ユビキチンタンパク質リガーゼXIAP市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Adamed Sp z oo、Astex Pharmaceuticals Inc、Bristol-Myers Squibb Company、F. Hoffmann-La Roche Ltd、Novartis AG、Noxopharm Ltd、Takeda Pharmaceutical Company Ltd
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Market Analysis and Insights: Global E3 Ubiquitin Protein Ligase XIAP Market
The global E3 Ubiquitin Protein Ligase XIAP market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global E3 Ubiquitin Protein Ligase XIAP Scope and Market Size
E3 Ubiquitin Protein Ligase XIAP market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global E3 Ubiquitin Protein Ligase XIAP market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the E3 Ubiquitin Protein Ligase XIAP market is segmented into
ASTX-660
FL-118
AD-O53.2
LCL-161
SM-1200
Others

Segment by Application, the E3 Ubiquitin Protein Ligase XIAP market is segmented into
Solid Tumor
Fallopian Tube Cancer
Lung Cancer
Peritoneal Cancer
Others

Regional and Country-level Analysis
The E3 Ubiquitin Protein Ligase XIAP market is analysed and market size information is provided by regions (countries).
The key regions covered in the E3 Ubiquitin Protein Ligase XIAP market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and E3 Ubiquitin Protein Ligase XIAP Market Share Analysis
E3 Ubiquitin Protein Ligase XIAP market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in E3 Ubiquitin Protein Ligase XIAP business, the date to enter into the E3 Ubiquitin Protein Ligase XIAP market, E3 Ubiquitin Protein Ligase XIAP product introduction, recent developments, etc.

The major vendors covered:
Adamed Sp z oo
Astex Pharmaceuticals Inc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Novartis AG
Noxopharm Ltd
Takeda Pharmaceutical Company Ltd

【レポートの目次】

1 Study Coverage
1.1 E3 Ubiquitin Protein Ligase XIAP Product Introduction
1.2 Market Segments
1.3 Key E3 Ubiquitin Protein Ligase XIAP Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global E3 Ubiquitin Protein Ligase XIAP Market Size Growth Rate by Type
1.4.2 ASTX-660
1.4.3 FL-118
1.4.4 AD-O53.2
1.4.5 LCL-161
1.4.6 SM-1200
1.4.7 Others
1.5 Market by Application
1.5.1 Global E3 Ubiquitin Protein Ligase XIAP Market Size Growth Rate by Application
1.5.2 Solid Tumor
1.5.3 Fallopian Tube Cancer
1.5.4 Lung Cancer
1.5.5 Peritoneal Cancer
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global E3 Ubiquitin Protein Ligase XIAP Market Size, Estimates and Forecasts
2.1.1 Global E3 Ubiquitin Protein Ligase XIAP Revenue 2015-2026
2.1.2 Global E3 Ubiquitin Protein Ligase XIAP Sales 2015-2026
2.2 Global E3 Ubiquitin Protein Ligase XIAP, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global E3 Ubiquitin Protein Ligase XIAP Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global E3 Ubiquitin Protein Ligase XIAP Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global E3 Ubiquitin Protein Ligase XIAP Competitor Landscape by Players
3.1 E3 Ubiquitin Protein Ligase XIAP Sales by Manufacturers
3.1.1 E3 Ubiquitin Protein Ligase XIAP Sales by Manufacturers (2015-2020)
3.1.2 E3 Ubiquitin Protein Ligase XIAP Sales Market Share by Manufacturers (2015-2020)
3.2 E3 Ubiquitin Protein Ligase XIAP Revenue by Manufacturers
3.2.1 E3 Ubiquitin Protein Ligase XIAP Revenue by Manufacturers (2015-2020)
3.2.2 E3 Ubiquitin Protein Ligase XIAP Revenue Share by Manufacturers (2015-2020)
3.2.3 Global E3 Ubiquitin Protein Ligase XIAP Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by E3 Ubiquitin Protein Ligase XIAP Revenue in 2019
3.2.5 Global E3 Ubiquitin Protein Ligase XIAP Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 E3 Ubiquitin Protein Ligase XIAP Price by Manufacturers
3.4 E3 Ubiquitin Protein Ligase XIAP Manufacturing Base Distribution, Product Types
3.4.1 E3 Ubiquitin Protein Ligase XIAP Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers E3 Ubiquitin Protein Ligase XIAP Product Type
3.4.3 Date of International Manufacturers Enter into E3 Ubiquitin Protein Ligase XIAP Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global E3 Ubiquitin Protein Ligase XIAP Market Size by Type (2015-2020)
4.1.1 Global E3 Ubiquitin Protein Ligase XIAP Sales by Type (2015-2020)
4.1.2 Global E3 Ubiquitin Protein Ligase XIAP Revenue by Type (2015-2020)
4.1.3 E3 Ubiquitin Protein Ligase XIAP Average Selling Price (ASP) by Type (2015-2026)
4.2 Global E3 Ubiquitin Protein Ligase XIAP Market Size Forecast by Type (2021-2026)
4.2.1 Global E3 Ubiquitin Protein Ligase XIAP Sales Forecast by Type (2021-2026)
4.2.2 Global E3 Ubiquitin Protein Ligase XIAP Revenue Forecast by Type (2021-2026)
4.2.3 E3 Ubiquitin Protein Ligase XIAP Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global E3 Ubiquitin Protein Ligase XIAP Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global E3 Ubiquitin Protein Ligase XIAP Market Size by Application (2015-2020)
5.1.1 Global E3 Ubiquitin Protein Ligase XIAP Sales by Application (2015-2020)
5.1.2 Global E3 Ubiquitin Protein Ligase XIAP Revenue by Application (2015-2020)
5.1.3 E3 Ubiquitin Protein Ligase XIAP Price by Application (2015-2020)
5.2 E3 Ubiquitin Protein Ligase XIAP Market Size Forecast by Application (2021-2026)
5.2.1 Global E3 Ubiquitin Protein Ligase XIAP Sales Forecast by Application (2021-2026)
5.2.2 Global E3 Ubiquitin Protein Ligase XIAP Revenue Forecast by Application (2021-2026)
5.2.3 Global E3 Ubiquitin Protein Ligase XIAP Price Forecast by Application (2021-2026)

6 North America
6.1 North America E3 Ubiquitin Protein Ligase XIAP by Country
6.1.1 North America E3 Ubiquitin Protein Ligase XIAP Sales by Country
6.1.2 North America E3 Ubiquitin Protein Ligase XIAP Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America E3 Ubiquitin Protein Ligase XIAP Market Facts & Figures by Type
6.3 North America E3 Ubiquitin Protein Ligase XIAP Market Facts & Figures by Application

7 Europe
7.1 Europe E3 Ubiquitin Protein Ligase XIAP by Country
7.1.1 Europe E3 Ubiquitin Protein Ligase XIAP Sales by Country
7.1.2 Europe E3 Ubiquitin Protein Ligase XIAP Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe E3 Ubiquitin Protein Ligase XIAP Market Facts & Figures by Type
7.3 Europe E3 Ubiquitin Protein Ligase XIAP Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific E3 Ubiquitin Protein Ligase XIAP by Region
8.1.1 Asia Pacific E3 Ubiquitin Protein Ligase XIAP Sales by Region
8.1.2 Asia Pacific E3 Ubiquitin Protein Ligase XIAP Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific E3 Ubiquitin Protein Ligase XIAP Market Facts & Figures by Type
8.3 Asia Pacific E3 Ubiquitin Protein Ligase XIAP Market Facts & Figures by Application

9 Latin America
9.1 Latin America E3 Ubiquitin Protein Ligase XIAP by Country
9.1.1 Latin America E3 Ubiquitin Protein Ligase XIAP Sales by Country
9.1.2 Latin America E3 Ubiquitin Protein Ligase XIAP Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America E3 Ubiquitin Protein Ligase XIAP Market Facts & Figures by Type
9.3 Central & South America E3 Ubiquitin Protein Ligase XIAP Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa E3 Ubiquitin Protein Ligase XIAP by Country
10.1.1 Middle East and Africa E3 Ubiquitin Protein Ligase XIAP Sales by Country
10.1.2 Middle East and Africa E3 Ubiquitin Protein Ligase XIAP Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa E3 Ubiquitin Protein Ligase XIAP Market Facts & Figures by Type
10.3 Middle East and Africa E3 Ubiquitin Protein Ligase XIAP Market Facts & Figures by Application

11 Company Profiles
11.1 Adamed Sp z oo
11.1.1 Adamed Sp z oo Corporation Information
11.1.2 Adamed Sp z oo Description and Business Overview
11.1.3 Adamed Sp z oo Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Adamed Sp z oo E3 Ubiquitin Protein Ligase XIAP Products Offered
11.1.5 Adamed Sp z oo Related Developments
11.2 Astex Pharmaceuticals Inc
11.2.1 Astex Pharmaceuticals Inc Corporation Information
11.2.2 Astex Pharmaceuticals Inc Description and Business Overview
11.2.3 Astex Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Astex Pharmaceuticals Inc E3 Ubiquitin Protein Ligase XIAP Products Offered
11.2.5 Astex Pharmaceuticals Inc Related Developments
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Corporation Information
11.3.2 Bristol-Myers Squibb Company Description and Business Overview
11.3.3 Bristol-Myers Squibb Company Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Bristol-Myers Squibb Company E3 Ubiquitin Protein Ligase XIAP Products Offered
11.3.5 Bristol-Myers Squibb Company Related Developments
11.4 F. Hoffmann-La Roche Ltd
11.4.1 F. Hoffmann-La Roche Ltd Corporation Information
11.4.2 F. Hoffmann-La Roche Ltd Description and Business Overview
11.4.3 F. Hoffmann-La Roche Ltd Sales, Revenue and Gross Margin (2015-2020)
11.4.4 F. Hoffmann-La Roche Ltd E3 Ubiquitin Protein Ligase XIAP Products Offered
11.4.5 F. Hoffmann-La Roche Ltd Related Developments
11.5 Novartis AG
11.5.1 Novartis AG Corporation Information
11.5.2 Novartis AG Description and Business Overview
11.5.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Novartis AG E3 Ubiquitin Protein Ligase XIAP Products Offered
11.5.5 Novartis AG Related Developments
11.6 Noxopharm Ltd
11.6.1 Noxopharm Ltd Corporation Information
11.6.2 Noxopharm Ltd Description and Business Overview
11.6.3 Noxopharm Ltd Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Noxopharm Ltd E3 Ubiquitin Protein Ligase XIAP Products Offered
11.6.5 Noxopharm Ltd Related Developments
11.7 Takeda Pharmaceutical Company Ltd
11.7.1 Takeda Pharmaceutical Company Ltd Corporation Information
11.7.2 Takeda Pharmaceutical Company Ltd Description and Business Overview
11.7.3 Takeda Pharmaceutical Company Ltd Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Takeda Pharmaceutical Company Ltd E3 Ubiquitin Protein Ligase XIAP Products Offered
11.7.5 Takeda Pharmaceutical Company Ltd Related Developments
11.1 Adamed Sp z oo
11.1.1 Adamed Sp z oo Corporation Information
11.1.2 Adamed Sp z oo Description and Business Overview
11.1.3 Adamed Sp z oo Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Adamed Sp z oo E3 Ubiquitin Protein Ligase XIAP Products Offered
11.1.5 Adamed Sp z oo Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 E3 Ubiquitin Protein Ligase XIAP Market Estimates and Projections by Region
12.1.1 Global E3 Ubiquitin Protein Ligase XIAP Sales Forecast by Regions 2021-2026
12.1.2 Global E3 Ubiquitin Protein Ligase XIAP Revenue Forecast by Regions 2021-2026
12.2 North America E3 Ubiquitin Protein Ligase XIAP Market Size Forecast (2021-2026)
12.2.1 North America: E3 Ubiquitin Protein Ligase XIAP Sales Forecast (2021-2026)
12.2.2 North America: E3 Ubiquitin Protein Ligase XIAP Revenue Forecast (2021-2026)
12.2.3 North America: E3 Ubiquitin Protein Ligase XIAP Market Size Forecast by Country (2021-2026)
12.3 Europe E3 Ubiquitin Protein Ligase XIAP Market Size Forecast (2021-2026)
12.3.1 Europe: E3 Ubiquitin Protein Ligase XIAP Sales Forecast (2021-2026)
12.3.2 Europe: E3 Ubiquitin Protein Ligase XIAP Revenue Forecast (2021-2026)
12.3.3 Europe: E3 Ubiquitin Protein Ligase XIAP Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific E3 Ubiquitin Protein Ligase XIAP Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: E3 Ubiquitin Protein Ligase XIAP Sales Forecast (2021-2026)
12.4.2 Asia Pacific: E3 Ubiquitin Protein Ligase XIAP Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: E3 Ubiquitin Protein Ligase XIAP Market Size Forecast by Region (2021-2026)
12.5 Latin America E3 Ubiquitin Protein Ligase XIAP Market Size Forecast (2021-2026)
12.5.1 Latin America: E3 Ubiquitin Protein Ligase XIAP Sales Forecast (2021-2026)
12.5.2 Latin America: E3 Ubiquitin Protein Ligase XIAP Revenue Forecast (2021-2026)
12.5.3 Latin America: E3 Ubiquitin Protein Ligase XIAP Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa E3 Ubiquitin Protein Ligase XIAP Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: E3 Ubiquitin Protein Ligase XIAP Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: E3 Ubiquitin Protein Ligase XIAP Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: E3 Ubiquitin Protein Ligase XIAP Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key E3 Ubiquitin Protein Ligase XIAP Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 E3 Ubiquitin Protein Ligase XIAP Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

...

【掲載企業】

Adamed Sp z oo、Astex Pharmaceuticals Inc、Bristol-Myers Squibb Company、F. Hoffmann-La Roche Ltd、Novartis AG、Noxopharm Ltd、Takeda Pharmaceutical Company Ltd

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のE3ユビキチンタンパク質リガーゼXIAP市場2026:インサイト・予測(Global E3 Ubiquitin Protein Ligase XIAP Market Insights and Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。